BMB-101 is under clinical development by Bright Minds Biosciences and currently in Phase II for Absence Seizure.

QRL-101 is under clinical development by QurAlis and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate (PTSR) indication ...

Patients would pay no more than $25 for certain name-brand medications to treat chronic illnesses, and face no costs for ...

Wish granted meaning Breakthrough in Alzheimer's disease imaging diagnosis: FDA approves first tau pathology imaging drug Breakthrough: New vitamin ...

Anavex Life Sciences' ANAVEX 2-73 shows promise in treating Alzheimer's, with strong efficacy in slowing cognitive and ...

Company Coverage includes Jazz Pharmaceuticals, UCB, Takeda Pharmaceutical, Biocodex, Longboard Pharmaceuticals, Stoke Therapeutics, Thermo Fisher Scientific, Harmony Biosciences Holdings, Ovid ...

Summary: Out-of-pocket costs for branded drugs for neurological diseases, particularly for multiple sclerosis (MS ... The ...

Blood pressure medications are usually taken for life. However, some people can stop taking them by addressing those underlying causes of high blood pressure (hypertension) that can be changed, such ...

Epilepsy, the most common neurological disorder, is characterized by seizures resulting from an imbalance between brain ...

Medically reviewed by Mary Choy, PharmD Ototoxicity is an adverse effect of some drugs. It is a condition that occurs when the inner ear is damaged by certain medications or chemicals, causing hearing ...

Disclaimer: This document does not constitute part of the Food and Drugs Act or its regulations. If there is any inconsistency or conflict between the act or regulations and this document, the act or ...

One large study from Germany showed a hazard ratio of 0.77 (95% CI 0.65-0.90) for epilepsy incidence among ARB users compared with users of other antihypertensive drug classes. An even larger U.S ...